Market Timing with TurnerTrends Provides Great Stock Picks for the Sophisticated Investor   Timing the Market well requires Stock Picks that work
Home Subscribe! Master Portfolios StockMasterPro ETFMasterPro Partners Members
Top 100 Stocks | Search Stocks | Sector Analyzer | Industry Analyzer
New Hot Stock Picks | How we Rate Stocks | Tutorial
My Stock Watch Lists: Add+
Ticker: 

TurnerTrends Stock Rating Report for ALTU

Data valid for week beginning July 21, 2008

Ticker Company Name
ALTU   [News] Altus Pharmaceuticals Inc
Company Profile
"Altus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of oral and injectable protein therapeutics for gastrointestinal and metabolic disorders. The company's products include ALTU-135, a Phase II completed clinical trial product is an orally-administered enzyme replacement therapy for the treatment of malabsorption due to exocrine pancreatic insufficiency- and ALTU-238, a Phase II completed clinical trial product is a crystallized formulation of human growth hormone (hGH) for the treatment of growth hormone deficiency in adults and hGH-related disorders. Its preclinical stage products comprise ALTU-237 for the treatment of hyperoxalurias and kidney stones- ALTU-236, which is designed to reduce the long-term effects associated with excess levels of phenylalanine- and ALTU-242 that is designed to reduce the long-term effects associated with excess levels of urate. The company has strategic alliances with Cystic Fibrosis Foundation Therapeutics, Inc. for the development of ALTU-135- and Genentech, Inc. to develop, manufacture, and commercializes ALTU-238, as well as collaboration agreement with Dr. Falk Pharma GmbH for commercializing ALTU-135 in Europe, the countries of the former Soviet Union, Israel, and Egypt. Altus Pharmaceuticals was incorporated in 1992. It was formerly known as Altus Biologics, Inc. and changed its name to Altus Pharmaceuticals, Inc. in 2004. The company is based in Cambridge, Massachusetts."

Join today to see our Technical, Fundamental, and Composite Stock Rating for this stock.
Technical Chart (3 year) Sector Chart Industry Chart

ALTU Technical Chart

We use technical analysis and fundamental analysis to recommend ratings for thousands of stocks. If you had a subscription, this space would show our 3 year history of trades for ALTU. However, we only show it to our subscribers.

We update our ratings and stop losses EVERY WEEK.

Don't miss out on what we recommend for Altus Pharmaceuticals Inc next week. Sign up today and start making money!

FREE TRIAL!!


Stock Information
Friday's Close $4.79
Volume Avg. 434396 shares
Industry Biotechnology
Sector Healthcare
Our Stop Loss Members Only
Expected Move Members Only
Optionable? Yes

Want to take a more "hands off" approach to investing with TurnerTrends? Try our managed accounts and hedge fund at Sabinal Capital Investments
Stock Financials
Profit Margin -237.65%
Operating Margin -225.75%
Debt-to-Equity .05%
P/E ttm 0.00
EPS ttm $-2.380
EBITDA $-64,820,000
Total Revenue $30,280,000
Market Cap $149,540
Annual Dividend $.00
Yield .000%
ROE -79.69%
Revenue Growth Rate Quarterly 217.00%
Earnings Growth Rate Quarterly 0.00%
Earnings Growth Rate Yearly 0.00%
Revenue Growth Rate Average 64.46%
Earnings Growth Rate Average 0.00%
Institutional Ownership Members Only
Value Rating Members Only
TurnerTrends Score Members Only


Latest News

Mon, 21 Jul 2008 12:41:41 Etc/GMTALTUS PHARMACEUTICALS INC. Files SEC form 8-K, Other Events (EDGAR Online)
Thu, 10 Jul 2008 12:42:30 Etc/GMTALTUS PHARMACEUTICALS INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Regulation FD Disclosure (EDGAR Online)
Wed, 9 Jul 2008 21:00:39 Etc/GMTAltus Pharmaceuticals signs long-term supply deal (AP)
Wed, 9 Jul 2008 20:07:00 Etc/GMTAltus Pharmaceuticals Secures Long-Term Growth Hormone Supply For ALTU-238 Clinical Development and Commercialization (Business Wire)
Mon, 7 Jul 2008 16:36:00 Etc/GMTAltus Pharmaceuticals Announces Webcast of Presentation at Collins Stewart Growth Conference (Business Wire)
Mon, 30 Jun 2008 18:16:09 Etc/GMTRussell 2000 adds 53 health care companies (AP)
Tue, 17 Jun 2008 14:12:00 Etc/GMTAltus Pharmaceuticals to Present at Upcoming Investor Conferences (Business Wire)
Fri, 13 Jun 2008 12:27:00 Etc/GMTAltus Pharmaceuticals Reports Last Patient Visit Of Trizytek(TM) Phase 3 Efficacy Trial (Business Wire)
Tue, 3 Jun 2008 12:27:00 Etc/GMTAltus Pharmaceuticals Reports ALTU-237 Phase 1 Clinical Trial Results (Business Wire)
Mon, 2 Jun 2008 14:40:52 Etc/GMTALTUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers (EDGAR Online)
Tue, 27 May 2008 20:31:53 Etc/GMTALTUS PHARMACEUTICALS INC. Files SEC form 8-K, Change in Directors or Principal Officers, Regulation FD Disclosure, F (EDGAR Online)
Thu, 22 May 2008 14:35:06 Etc/GMTAltus turns to Genzyme exec for next CEO (at bizjournals.com)
Thu, 22 May 2008 13:26:00 Etc/GMTAltus Pharmaceuticals names Georges Gemayel CEO (AP)
Thu, 22 May 2008 12:32:00 Etc/GMTAltus Pharmaceuticals Appoints Georges Gemayel Chief Executive Officer and Member of Board of Directors (Business Wire)
Sat, 10 May 2008 13:05:03 Etc/GMTALTUS PHARMACEUTICALS INC. Financials (EDGAR Online Financials)
Wed, 7 May 2008 12:27:00 Etc/GMTAltus Pharmaceuticals Reports First Quarter Results (Business Wire)
Wed, 7 May 2008 11:07:56 Etc/GMTQ2 2008 Altus Pharmaceuticals Inc. Earnings Release - Before Market Open (CCBN)
Wed, 7 May 2008 10:02:56 Etc/GMTALTUS PHARMACEUTICALS INC. Files SEC form 10-Q, Quarterly Report (EDGAR Online)
Wed, 30 Apr 2008 12:37:00 Etc/GMTAltus Pharmaceuticals to Host First Quarter Investor Conference Call on May 7, 2008 (Business Wire)
Tue, 29 Apr 2008 12:37:00 Etc/GMTAltus Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference (Business Wire)
News provided by Yahoo! Finance
Home | Stock Portfolios | Stock Ratings | Top 100 Stocks | New Hot Stock Picks | Sector Analyzer | Industry Analyzer | Member's Area | Articles | FAQ | Contact Us | Terms of Use | Advertise
(C) Copyright TurnerTrends, Inc.  All Rights Reserved.

*Past performance does not guarantee future results. TurnerTrends makes no representations or warrants that just because a stock would have made a profit in the past, using TurnerTrends buy recommendations or sell recommendations, it will make any profits in the future. It is possible that these same stocks will lose money in the future using the TurnerTrends stock recommendations.

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither TurnerTrends nor any of its data or content providers shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the TurnerTrends site, a user agrees not to redistribute the information found therein.